Nose Spray Approved as EpiPen Alternative

A new nasal spray version of epinephrine, designed as an alternative to traditional auto-injectors like EpiPen, has received FDA approval for emergency treatment of severe allergic reactions, including anaphylaxis. Approved on August 9, the spray is intended for adults and children weighing over 66 pounds. This development has sparked excitement among some medical professionals, who see it as a potential solution to the low rates of auto-injector usage among high-risk patients. Dr. J. Andrew Bird, a pediatric allergist, highlights that only about 40% of patients at high risk for severe allergic reactions carry their auto-injectors, often due to inconvenience, forgetfulness, or a false sense of security regarding their allergies. While the nasal spray could address these issues, concerns remain about its effectiveness, particularly in situations where nasal passages may be blocked during an allergic reaction. The manufacturer, ARS, is currently working with major insurance companies to secure coverage for the new spray, a process that could take up to six months. In the interim, some physicians may hesitate to prescribe the spray immediately due to the administrative burden of obtaining insurance approval, as noted by Dr. Kaufman. Despite these concerns, Dr. Wood expresses willingness to prescribe the nasal spray once available, likely by late September, while advising patients to keep an auto-injector on hand as a precaution. If the nasal spray proves effective, it could significantly change the landscape of allergy treatment.